Table 2 Correlation of tumor PLK4 IHC scores with features
Features | Tumor PLK4 IHC score | P value | |||
|---|---|---|---|---|---|
0 (n= 37) | 1-3 (n = 35) | 4-6 (n = 39) | 7-12 (n = 31) | ||
Age, No. (%) | 0.346 | ||||
<60 years | 14 (37.8) | 20 (57.1) | 21 (53.8) | 14 (45.2) | |
≥60 years | 23 (62.2) | 15 (42.9) | 18 (46.2) | 17 (54.8) | |
Menopausal status, No. (%) | 0.916 | ||||
Pre-menopause | 8 (21.6) | 8 (22.9) | 8 (20.5) | 5 (16.1) | |
Post-menopause | 29 (78.4) | 27 (77.1) | 31 (79.5) | 26 (83.9) | |
Diabetes, No. (%) | 0.055 | ||||
No | 26 (70.3) | 24 (68.6) | 36 (92.3) | 23 (74.2) | |
Yes | 11 (29.7) | 11 (31.4) | 3 (7.7) | 8 (25.8) | |
Hypertension, No. (%) | 0.815 | ||||
No | 20 (54.1) | 22 (62.9) | 25 (64.1) | 19 (61.3) | |
Yes | 17 (45.9) | 13 (37.1) | 14 (35.9) | 12 (38.7) | |
Histological subtype, No. (%) | 0.408 | ||||
Endometrioid carcinoma G1/G2 | 23 (62.2) | 27 (77.1) | 29 (74.4) | 17 (54.8) | |
Endometrioid carcinoma G3 | 3 (8.1) | 3 (8.6) | 3 (7.7) | 6 (19.4) | |
Serous endometrial carcinoma | 8 (21.6) | 3 (8.6) | 5 (12.8) | 3 (9.7) | |
Clear cell endometrial carcinoma | 3 (8.1) | 2 (5.7) | 2 (5.1) | 5 (16.1) | |
Myometrial invasion ≥50%, No. (%) | 0.130 | ||||
No | 28 (75.7) | 20 (57.1) | 24 (61.5) | 15 (48.4) | |
Yes | 9 (24.3) | 15 (42.9) | 15 (38.5) | 16 (51.6) | |
Cervical invasion, No. (%) | 0.085 | ||||
None or epithelial | 31 (83.8) | 26 (74.3) | 31 (79.5) | 18 (58.1) | |
Stromal | 6 (16.2) | 9 (25.7) | 8 (20.5) | 13 (41.9) | |
Lymphovascular invasion, No. (%) | 0.008 | ||||
No | 34 (91.9) | 21 (60.0) | 31 (79.5) | 20 (64.5) | |
Yes | 3 (8.1) | 14 (40.0) | 8 (20.5) | 11 (35.5) | |
FIGO stage, No. (%) | 0.005 | ||||
I | 29 (78.4) | 19 (54.3) | 27 (69.2) | 13 (41.9) | |
II | 5 (13.5) | 2 (5.7) | 4 (10.3) | 7 (22.6) | |
III | 3 (8.1) | 10 (28.6) | 5 (12.8) | 5 (16.1) | |
IV | 0 (0.0) | 4 (11.4) | 3 (7.7) | 6 (19.4) | |
CA125 abnormity, No. (%) | 0.148 | ||||
No | 28 (75.7) | 22 (62.9) | 30 (76.9) | 17 (54.8) | |
Yes | 9 (24.3) | 13 (37.1) | 9 (23.1) | 14 (45.2) | |
CA19-9 abnormity, No. (%) | 0.327 | ||||
No | 27 (73.0) | 27 (77.1) | 29 (74.4) | 18 (58.1) | |
Yes | 10 (27.0) | 8 (22.9) | 10 (25.6) | 13 (41.9) | |
CEA abnormity, No. (%) | 0.659 | ||||
No | 25 (67.6) | 19 (54.3) | 25 (64.1) | 18 (58.1) | |
Yes | 12 (32.4) | 16 (45.7) | 14 (35.9) | 13 (41.9) | |
Adjuvant radiotherapy, No. (%) | 0.298 | ||||
No | 11 (29.7) | 11 (31.4) | 6 (15.4) | 6 (19.4) | |
Yes | 26 (70.3) | 24 (68.6) | 33 (84.6) | 25 (80.6) | |
Adjuvant chemotherapy, No. (%) | 0.181 | ||||
No | 28 (75.7) | 19 (54.3) | 29 (74.4) | 20 (64.5) | |
Yes | 9 (24.3) | 16 (45.7) | 10 (25.6) | 11 (35.5) | |